ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth - Regular Plan

  • Previous Nav

  • Net Change on 07-07-2020

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

To generate long-term capital appreciation by creating a portfolio that is invested in Equity and Equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.However there can be no assurance that the investment objectives of the scheme will be realized.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
S&P BSE Health Care 0.75 20.56 28.00 4.21 -0.85 13.89

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Growth Plan-Growth Jun 05, 2004 34.53 13.65 6.68 2.24 2,991.57
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH Jul 14, 1999 34.03 4.94 0.25 2.33 1,138.75
UTI Healthcare Fund - Regular Plan - Growth Option Aug 01, 2005 34.06 7.78 1.84 2.53 474.52

Fund Holdings as on 31-May-2020

  • Cipla Ltd.

  • Sun Pharmaceutical Industries Ltd.

  • Lupin Ltd.

  • TREPS

  • Biocon Ltd.

  • J.B.Chemicals & Pharmaceuticals Ltd.

  • Cadila Healthcare Ltd.

  • Sanofi India Ltd.

  • Natco Pharma Ltd.

  • Divi's Laboratories Ltd.

  • Torrent Pharmaceuticals Ltd.

  • Alembic Pharmaceuticals Ltd.

  • Laurus Labs Ltd.

  • Syngene International Ltd.

  • SBI Life Insurance Company Ltd.

  • Indoco Remedies Ltd.

  • Narayana Hrudayalaya Ltd.

  • Aster DM Healthcare Ltd.

  • Dr. Reddy's Laboratories Ltd.

  • Tata Chemicals Ltd.

  • Neuland Laboratories Ltd.

  • IPCA Laboratories Ltd.

  • FDC Ltd.

  • Dishman Carbogen Amcis Ltd.

  • Aurobindo Pharma Ltd.

  • Panacea Biotec Ltd.

  • Astrazeneca Pharma India Ltd.

  • Healthcare Global Enterprises Ltd.

  • Alkem Laboratories Ltd.

  • Fortis Healthcare Ltd.

  • Net Current Assets

  • HDFC Bank Ltd. - 17 Aug 2020 (Duration - 91 Days)

  • Gufic Biosciences Ltd.

  • Glaxosmithkline Pharmaceuticals Ltd.

  • Neogen Chemicals Ltd.

  • Max India Ltd.

  • Cash Margin - Derivatives

View More
  • Pharmaceuticals & Drugs

  • Miscellaneous

  • Hospital & Healthcare Services

  • Insurance

  • Chemicals

  • Finance - Investment

View More

Fund Manager

  • Cash

  • Deposits

  • Equity

View More

About ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund

Scheme Analysis

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to ICICI Prudential Mutual Fund. It was launched on 13-Jul-2018 and currently has an AUM of ₹1,460.01 crore. ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is benchmarked against NIFTY 50 - TRI as primary index and S&P BSE Health Care as secondary index.

The NAV of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund ended up ₹0(0%)yesterday to ₹13.15.

Among its top 3 holdings the fund has exposure to Cipla Ltd., and

The ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is managed by Priyanka Khandelwal and Dharmesh Kakkad.

Fund House Contact

One BKC, A - Wing 13th Floor, Bandra Kurla Complex, Bandra (East) Mumbai - 400 051

+91 (22) 2652 5000
enquiry@icicipruamc.com
+91 (22) 2652 8100